Treatment of lupus mice with PPARβ/δ agonist reduced incidence of hypertension, endothelial disfunction, renal inflammation, and organ damage of mice, which was associated with decreased plasma anti-double-stranded DNA autoantibodies and anti-inflammatory, antioxidant effects (Romero et al., 2017). Here, PPARD is linked to systemic lupus erythematosus.